PROPOSED SHARE SPLIT OF EVERY ONE (1) EXISTING ORDINARY SHARE IN THE CAPITAL OF SAMURAI 2K AEROSOL LIMITED INTO THREE (3) ORDINARY SHARES INTRODUCTION The Board of Directors (the Board ) of Samurai 2K Aerosol Limited (the Company , together with its subsidiaries, the Group ) wishes to announce that the Company is proposing a share split of every one (1) existing ordinary share in the capital of the Company ( Share ) held by shareholders of the Company ( Shareholders ) as of a record date (the Record Date ) to be determined by the Board in due course, into three (3) Shares (the Proposed Share Split ). TERMS OF THE PROPOSED SHARE SPLIT
General Announcement::Announcement Pursuant to Rule 706A of the Catalist Rules marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
) CHANGE OF REGISTERED ADDRESS OF THE MANAGER ESR Funds Management Limited, the manager of ESR-REIT , wishes to inform that with effect. | May 22, 2021
Lonza Group AG: Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp
New agreement for three further production lines at Lonza s site in Visp, Switzerland
Additional production lines will come online sequentially
All three are expected to be operational in the earlier part of 2022
Quote from Pierre-Alain Ruffieux, CEO, Lonza: Since we began working with Moderna in May 2020, its mRNA vaccine has proved to be pivotal in controlling the COVID-19 pandemic. We have commenced and ramped up operations in our four existing production lines at an unprecedented rate and scale. Our new agreement with Moderna will double our drug substance manufacturing capacity in Visp (CH), at this time of urgent global demand. We are proud of our work with Moderna, and we are looking forward to expanding the partnership in the coming months.